A review on noscapine, and its impact on heme metabolism

Current Drug Metabolism

Volumn 14, Issue 3, 2013, Pages 351-360

  Singh, Harpal ^a   Singh, Prashant ^a,b,c   Kumari, Kamlesh ^d   Chandra, Ankush ^e   Dass, Sujata K ^f   Chandra, Ramesh ^a  

^a UNIVERSITY OF DELHI   (India)

^b BABASAHEB BHIMRAO AMBEDKAR UNIVERSITY   (India)

^c UNIVERSITY OF DELHI   (India)

^d MOTILAL NEHRU NATIONAL INSTITUTE OF TECHNOLOGY   (India)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF DELHI   (India)

Author keywords

Alanine transaminase (ALT); And bilirubin; Biliverdin; Cytochrome P450; Glutathione S transferases (GSTs); L (SR) Noscapine

Indexed keywords

ANTITOXIN; AZATHIOPRINE; BILIRUBIN; BLEOMYCIN; CARBOPLATIN; CATALASE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; COLCHICINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DACTINOMYCIN; DEMECOLCINE; DOXORUBICIN; EPIRUBICIN; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; HEME OXYGENASE; IFOSFAMIDE; MERCAPTOPURINE; NALOXONE; NOCODAZOLE; NOSCAPINE; OXALIPLATIN; TUMOR MARKER;

ABDOMINAL DISCOMFORT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AQUEOUS SOLUTION; AREA UNDER THE CURVE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHEMOPROPHYLAXIS; CONTROLLED DRUG RELEASE; DNA POLYMORPHISM; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG SYNTHESIS; FIRST PASS EFFECT; GENOTOXICITY; GENOTYPE; GLIOBLASTOMA; HUMAN; LYMPHOMA; MELANOMA; MICROTUBULE; MYELOID LEUKEMIA; NAUSEA; NONHUMAN; OVARY TUMOR; OXIDATIVE STRESS; PHENOTYPE; REVIEW; SEDATION; SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTITUSSIVE AGENTS; CELL CYCLE; HEME; HUMANS; MICROTUBULES; NEOPLASMS; NOSCAPINE;

EID: 84877949750     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200211314030010     Document Type: Review

References (67)

1. Amos, L. Microtubule structure and its stabilization. Org. Biomol. Chem., 2004, 2, 2153-2160.
2. Anderson, J.T.; Ting, A.E.; Boozer, S.; Brunden K.R.; Crumrine, C.; Danzig, J.; Dent, T.; Faga, L.; Harrington, J.J.; Hodnick, W.F.; Murphy, S.M.; Pawlowski. G.; Perry. R.; Raber, A.; Rundlett. S.E.; Stricker-Krongrad, A.; Wang, J.; Bennani, Y.L. Identification of novel and improved antimitotic agents derived from noscapine. J. Med. Chem., 2005, 48, 7096-7098. (Pubitemid 41743622)
3. Anderson, J.T.; Ting, A.E.; Boozer, S.; Brunden, K.R.; Danzig, J.; Dent, T.; Harrington, J.J.; Murphy, S.M.; Perry, R.; Raber, A.; Rundlett. S.E.; Wang, J.; Wang, N.; Bennani, Y.L. Discovery of Sphase arresting agents derived from noscapine. J. Med. Chem., 2005, 48, 2756-2758. (Pubitemid 40548089)
4. Aneja, R,; Dhiman, N.; Idnani, J.; Awasthi, A.; Arora, S.K.; Chandra, R.; Joshi, H.C. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol., 2007, 60, 831-839. (Pubitemid 47389389)
5. Aneja, R.; Zhou, J.; Vangapandu, S.N.; Zhou, B.; Chandra, R.; Joshi, H.C. Drug-resistant T-lymphoid tumors undergo apoptosis. Blood, 2006, 107, 2486-2492.
6. Bishop, J.M. Molecular themes in oncogenesis. Cell, 1991, 64, 235-248.
7. Chopra, R.N.; Mukherjee, B.; Dikshit, B.B. Narcotine: its pharmacological action and therapeutic uses. Indian J. Med. Res., 1930, 18, 35-49.
8. Dahlstrom, B.; Mellstrand, T.; Lofdahl, C.G.; Johansson, M.; Pharmacokinetic properties of noscapine. Eur. J. Clin. Pharmacol., 1982, 22 (6), 535-539. (Pubitemid 12059199)
9. Espinosa, E.; Zamora, P.; Feliu, J.; Baron, M.G. Classification of anticancer drugs-A new system based on therapeutic targets. Cancer Treatment Rev., 2003, 29, 515-523. (Pubitemid 37428323)
10. Foulds, L. The natural history of cancer. J. Chronic Dis., 1958, 8, 2-37.
11. Gibaldi, M.; Weiner, N. Biphasic elimination of noscapine. J. Pharm. Sci., 1966, 55, 761-763.
12. Heidari, N.; Goliaei, B.; Moghaddam, P.R.; Rahbar-Roshandel, N.; Mahmoudian, M. Apoptotic pathway induced by noscapine in human myelogenous leukemic cells. Anticancer Drugs, 2007, 18, 1139-1147. (Pubitemid 47480738)
13. Hurley, L.H. DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer, 2002, 2, 188-200. (Pubitemid 37328788)
14. Ieri, E.; Ercan, M.T.; Ka, H.S.; Hincal, A.A. The in-vivo distribution of the 99mTc-labeled albumin and gelatin microspheres of a tuberculostatic agent, rifampicin. Boll. Chim. Farm., 1991, 130, 66-70.
15. Jordan, M.A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem., 2002, 2, 1-17. (Pubitemid 34649866)
16. Karlsson, M.O.; Dahlstrom, B.; Eckernas, S.A.; Johansson, M.; Alm, A.T. Pharmacokinetics of oral noscapine. Eur. J. Clin. Pharmacol., 1990, 39, 275-279. (Pubitemid 20336147)
17. Ke, Y.; Ye, K.; Grossniklaus, H.E.; Archer, D.R. Joshi, H.C.; Kapp, J.A. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol. Immunother., 2000, 49, 217-225. (Pubitemid 30484828)
18. Landen, J.W.; Hau, V.; Wang, M.; Davis, T.; Ciliax, B.; Wainer, B.H.; Van, Meir, E.G.; Glass, J.D.; Joshi, H.C.; Archer, D.R. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin. Cancer Res., 2004, 10, 5187-5201. (Pubitemid 39099794)
19. Landen, J.W.; Lang, R.; McMahon, S.J.; Rusan, N.M.; Yvon, A.M.; Adams, A.W.; Sorcinelli, M.D.; Campbell, R.; Bonaccorsi, P.; Ansel, J.C.; Archer, D.R.; Wadsworth, P.; Armstrong, C.A.; Joshi, H.C. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res., 2002, 62, 4109-4114. (Pubitemid 34791082)
20. Liu, Y.; Chen, G.S.; Chen, Y.; Ding, F.; Chen, J. Cyclodextrin as carriers for cinchona alkaloids: a pH-responsive selective binding system. Org. Biomol. Chem., 2005, 3, 2519-2523. (Pubitemid 41068487)
21. Lu, M.C. In Cancer Chemotherapy Agents. Ed. W.O. Foye, American Chem. Soc., Washington DC, 1995, 345-368.
22. Mitchell, I.D.; Carlton, J.B.; Chan, M.Y.; Robinson, A.; Sunderland, J. Noscapine-induced polyploidy in vitro. Mutagenesis, 1991, 6, 479-486.
23. Nayak, K.P.; Brochmann-Hanssen.; Leong-way, E. Biological disposition of noscapine. J. Pharm. Sci., 1965, 54, 191-194.
24. Nogales, E. Structural insight in to microtubule function. Annu. Rev. Biophys. Biomol. Struct., 2001, 30, 397-420.
25. Reynold, R.J.; Schecker, J.A. Radiation, cell cycle and cancer. Los. Almos. Sci., 1995, 23, 51-89.
26. Rose, W.C.; Long, B.H.; Fairchild, C.R.; Lee, F.Y.; Kadow, J.F. Preclinical pharmacology of BMS-275183, an orally active taxane. Clin. Cancer Res., 2001, 7, 2016-2021. (Pubitemid 32994840)
27. Rowinsky, E.K. The development and clinical utility of the taxanes class of antimicrotubule chemotherapy agents. Annu. Rev. Med., 1997, 48, 353-374. (Pubitemid 27101837)
28. Tiveron, C.; Hartley-Asp, B.; Johansson, C.J.; Pacchierotti, F. Noscapine does not show aneugenic activity in mouse oocyte. Mutagenesis, 1993, 8, 311-315. (Pubitemid 23226773)
29. Valiron, O.; Caudron, N.; Job, D. Microtubule dynamics. Cell Mol. Life Sci., 2001, 58, 2069-2084. (Pubitemid 34016976)
30. Vedso, S. The determination of noscapine (narcotine) in plasma and urine. Acta. Pharmacol. Toxicol., 1961, 18, 119-128.
31. Weinberg, R.A. Oncogenes, antioncogenes and the molecular basis of multistep carcinogenesis. Cancer Res., 1989, 49, 3713-3721. (Pubitemid 19197385)
32. Winter, C.A.; Flataker, L. Antitussive compounds; testing methods and results. J. Pharmacol. Exp. Ther., 1954, 112, 99-108.
33. Winter, C.A.; Flataker, L. Toxicity studies on noscapine. Toxicol. Appl. Pharmacol., 1961, 3, 96-106.
34. Ye, K.; Ke, Y.; Keshava, N.; Shanks, J.; Kapp, J.A.; Tekmal, R.R.; Petros, J.; Joshi, H.C. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc. Natl. Acad. Sci. USA, 1998, 95, 1601-1606. (Pubitemid 28103439)
35. Zhou, J.; Giannakakou, P. Anticancer agents targeting microtubules for cancer chemotherapy. Curr. Med. Chem., 2005, 5, 65-71. (Pubitemid 40081295)
36. Zhou, J.; Gupta, K.; Aggarwal, S.; Aneja, R.; Chandra, R.; Panda, D.; Joshi, H.C. Brominated derivatives of noscapine are potent microtubule- interfering agents that perturb mitosis and inhibit cell proliferation. Mol. Pharmacol., 2003, 63, 799-807. (Pubitemid 36368986)
37. Zhou, J.; Gupta, K.; Yao, J.; Ye, K.; Panda, D.; Giannakakou, P.; Joshi, H.C. Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J. Biol. Chem., 2002, 277, 39777-39785. (Pubitemid 35190961)
38. Zhou, J.; Liu, M.; Luthra, R.; Jones, J.; Aneja, R.; Chandra, R.; Tekmal, R.R.; Joshi, H.C. EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice. Cancer Chemother. Pharmacol., 2005, 55, 461-465. (Pubitemid 40568976)
39. Cooper, G.M. "Chapter 14: The Eukaryotic Cell Cycle". The cell: a molecular approach (2nd ed.). Washington, D.C: ASM Press. 2000, ISBN 0-87893-106-6 http://www.ncbi.nlm.nih.gov/books/NBK9876/.
40. King, R. Cancer Biology. Essex, England: Pearson Eduction. 2006, 146.
41. Rubenstein.; Irwin.; Susan, M. Wick. "Cell." World Book Online Reference Center. 2008.
42. De Souza, C.P.; Osmani, S.A. "Mitosis, not just open or closed". Eukaryotic Cell., 2007, 6, 1521-7. doi:10.1128/EC.00178-07. PMC 2043359. PMID 17660363. (Pubitemid 47483595)
43. Available from: http://en.wikipedia.org/wiki/Cell-cycle
44. Landen, J.W.; Lang, R.; McMohan, S.J.; Rusan, N.M.; Yvon, A.M.; Adams, A.W.; Sorcinelli, M.D.; Campbell, R.; Bonaccorsi, P.; Ansel, J.C.; Archer, D.R.; Wadsworth, P.; Armstrong, C.A.; Joshi, H.C. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Clin. Cancer Res., 2002, 62, 4109-4114. (Pubitemid 34791082)
45. Aneja, R.; Vangapandu, S.N.; Lopus, M.; Chandra, R.; Panda, D.; Joshi, H.C. Development of a novel nitro-derivative of noscapine for the potential treatment of drug resistant ovarian cancer and Tcell lymphoma. Mol. Pharmacol., 2006, 69, 1801-1809. (Pubitemid 43894296)
46. Aneja, R.; Zhou, J.; Zhou, B.; Chandra, R.; Joshi, H.C. Treatment of harmone-refractory breast cancer: apoptosis and regression of human tumours implanted in mice. Mol. Cancer Ther., 2006, 5, 2366-2377. (Pubitemid 44530474)
47. Mahmoudian, M.; Siadatpour, A.; Ziai, S.A.; Mehrpour, M.; Benaissa, F.; Nobakht M. Reduction of the prenatal hypoxicischemic brain edema with noscapine. Acta Physiol. Hung., 2003, 90, 313-318 (Pubitemid 38036469)
48. Mahmoudian, M.; Mehrpour, M.; Benaissa, F.; Siadatpour, Z. A preliminary report on the application of noscapine in the treatment of stroke. Eur. J. Clin. Pharmacol., 2003, 59, 579-581. (Pubitemid 37494523)
49. Graham, M.A.; Riley, R.J. ; Kerr, D.J. Drug metabolism in carcinogenesis and cancer chemotherapy Pharmacology & Therapeutics 1991, 51 (2), 275-289
50. Sung, B.; Ahn, K.S.; Aggarwal, B. B. Noscapine, a benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-B signaling pathway. Cancer Res., 2010, 70, 3259-3268.
51. Newcomb, E.W.; Lukyanov, Y.; Schnee, T.; Ali, M.A.; Lan, L.; Zagzag, D. Noscapine inhibits hypoxia-mediated HIF-1 expression and angiogenesis in vitro: a novel function for an old drug. Int J. Oncol., 2006, 28, 1121-1130.
52. Newcomb, E.W.; Lukyanov, Y.; Basanta M.A.; Esencay, M.; Smirnova, I.; Schnee, T.; Shao, Y.; Devitt, M.L.; Zagzag, D.; McBride, W.; Formenti, S.C. Antiangiogenic effects of noscapine enhance radio response for GL261 tumours. Int. J. Radiat. Oncol. Biol. Phys., 2008, 71, 1477-1484. (Pubitemid 351978170)
53. Karna, P.; Rida, P.C.; Pannu, V.; Gupta, K.K.; Dalton, W.B.; Joshi, H.; Yang, V.W.; Zhou, J.; Aneja, R. A novel microtubulemodulating noscapinoid triggers apoptosis by inducing spindle multipolarity via centrosome amplification and declustering. Cell Death Differ., 2011, 18, 632-644.
54. Aneja, R.; Miyagi, T.; Karna, P.; Ezell, T.; Shukla, D.; Gupta, M.V.; Yates, C.; Chinni, S.R.; Zhau, H.; Chung, L.W.; Joshi, H.C. A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells. Eur. J. Cancer., 2010, 46, 1668-1678.
55. Buchler, J.W. Synthesis and properties of metalloporphyrins. In: Dolphin D, editor. Porphyrins, vol. 1. New York: Academic Press; 1978, 389-483.
56. Desnick, R.J; Anderson KE. Heme biosynthesis and its disorders: porphyrias and sideroblastic anemias. In: Hematology: Basic Principles and Practice. 2nd ed. New York: Churchill Livingstone. 1995, 523-545.
57. William, J.A.M. Textbook of biochemistry with clinical correlation. John Wiley and Sons, INC, Newyork 1997.
58. Kappas, A.; Sassa,S.; Anderson, K.E.; In The Metabolic Basis of Inherited Disease\ (Stanbury, J. B.; Wyngaarden, J. B.; Fredrickson, D. S.; Goldstein, J. L.; and Brown, M. S.; eds.), 5th ed. McGraw-Hill, New York, 1983, pp. 1301-1384.
59. Jain, D. Hepatic mitochondria1 membrane chemistry and heme metabolism in relation to multidentate macromolecules. M.Phi1. dissertation, submitted to the University of Delhi 1989.
60. Parizek, J. In Effects and Dose Response Relationship of Trace Metals (Nordberg, G. H., ed.), Elsevier, Amsterdam. 1976, 498-510.
61. Margie L.C.; Christine E.S. Glutathione S-transferases-biomarkers of cancer risk and chemopreventive response. Chemico-Biological Interactions, 1998, 111, 377-388
62. Casagrande, S.; Bonetto, V.; Fratelli, M.; Gianazza, E.; Eberini, I.; Massignan, T.; Salmona, M.; Chang, G.; Halmgren, A.; Ghezzi, P. Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc. Natl. Acad. Sci. USA 2002, 99, 9745-9749. (Pubitemid 34831118)
63. Kidd, P.M. Glutathione: Systemic Protectent Against Oxidative and Free Radical Demage Altern. Med. Rev., 1997, 2, 155-176 (Pubitemid 127735670)
64. Shen, H.; Tsuchida, S.; Tamai, K.; Sato, K.; Identication of cysteine residues involved in disulde formation in the inactivation of glutathione transferase P-form by hydrogen peroxide. Arch. Biochem. Biophys. 1993, 300, 137-141. (Pubitemid 23225728)
65. Tew, K.D. Glutathione-associated enzymes in anticancer drug resis-tance. Cancer Res., 1994, 54, 4313-4320. (Pubitemid 24273141)
66. Smith, C.M.; Kelsey, K.T.; Wiencke, J.K.; Leyden, K.; Levin, S.; Christiani, D.C. Inherited glutathione-S-transferase deciency is a risk factor for pulmonary asbestosis. Cancer Epidemiol. Biomarkers Prev., 1994, 3, 471-477. (Pubitemid 24280970)
67. Nelson, H.H.; Wiencke, J.K.; Christiani, D.C.; Cheng, T.J.; Zuo, Z.F.; Schwartz, B.S.; Lee, B.K.; Spitz, M.R.; Wang, M.; Xu, X.; Kelsey, K.T. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis, 1995, 6, 1243-1245.